Immune checkpoint inhibitors (ICI), especially anti-PD-1/PD-L1 antibodies, have been widely used as an effective therapy for many types of cancer, with impressive long-lasting responses in patients with non-small cell lung cancer (NSCLC) (1–3). The gene discussed is CD274; the disease is non-small cell lung carcinoma.